Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06627088 · ClinicalTrials.gov registry record · Phase 1
A Study of LY4100511 (DC-853) Mass Balance and Absolute Bioavailability of LY4100511 in Healthy Male Participants
A Phase 1 study, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT06627088: Completed Phase 1 study, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company.
NCT06627088 is a Phase 1 study that has completed, run by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06627088, a Phase 1 study, has completed, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The study has two parts, Part A and Part B. The purpose of Part A is to determine the absorption, metabolism, and excretion (AME) of \[14C\]-LY4100511 and to characterize and determine the metabolites present in plasma, urine, and feces in healthy male participants after a single oral dose of LY4100511. The purpose of Part B is to determine the absolute bioavailability of LY4100511 in humans, to further analyze the rate and routes of excretion, including the mass balance, and to further investigate the pharmacokinetics (PK) of \[14C\]-LY4100511, LY4100511, and TRA.
Primary Outcome
Total radioactivity recovery and excretion (fet1-t2 and Aet1-t2) in urine and feces (and vomitus, if available)
Interventions
- DRUG LY4100511 (DC-853)
- DRUG [14C]-LY4100511 (DC-853) Administered oral dose
- DRUG [14C]-LY4100511 (DC-853)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-08-23 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 1 |
What the finished NCT06627088 record still lists
NCT06627088 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 3 interventions - of which LY4100511 (DC-853) is the first listed.
NCT06627088 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06627088 about?
NCT06627088 is a clinical study titled "A Study of LY4100511 (DC-853) Mass Balance and Absolute Bioavailability of LY4100511 in Healthy Male Participants". The study has two parts, Part A and Part B. The purpose of Part A is to determine the absorption, metabolism, and excretion (AME) of \[14C\]-LY4100511 and to characterize and determine the metabolites present in plasma, urine, and feces in healthy male participants after a single oral dose of LY4100...
What is the current status of trial NCT06627088?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-08-23. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT06627088?
The interventions under investigation include: LY4100511 (DC-853) (DRUG), [14C]-LY4100511 (DC-853) Administered oral dose (DRUG), [14C]-LY4100511 (DC-853) (DRUG).
Who is sponsoring clinical trial NCT06627088?
This trial is sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06627088's enrollment target sits among peer trials
24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI